Page 155 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 155
165. Marr PL, Elkin EP, Arredondo SA, et al. 175. Wu H, Sun L, Moul JW, et al. Watchful
Comorbidity and primary treatment for waiting and factors predictive of secondary
localized prostate cancer: data from treatment of localized prostate cancer. J Urol
CaPSURE. J Urol 2006;175:1326-1331. 2004;171:1111-1116.
166. Shavers VL, Brown ML, Potosky AL, et al. 176. Carter CA, Donahue T, Sun L, et al.
Race/ethnicity and the receipt of watchful Temporarily deferred therapy (watchful
waiting for the initial management of waiting) for men younger than 70 years and
prostate cancer. J Gen Intern Med with low-risk localized prostate cancer in the
2004;19:146-155. prostate-specific antigen era. J Clin Oncol
167. Meng MV, Elkin EP, Harlan SR, et al. 2003;21:4001-4008.
Predictors of treatment after initial 177. Yan Y, Carvalhal GF, Catalona WJ, et al.
surveillance in men with prostate cancer: Primary treatment choices for men with
results from CaPSURE. J Urol clinically localized prostate carcinoma
2003;170:2279-2283. detected by screening. Cancer
2000;88:1122-1130.
168. Koppie TM, Grossfeld GD, Miller D, et al.
Patterns of treatment of patients with 178. Sommers BD, Beard CJ, D’Amico AV,
prostate cancer initially managed with Kaplan I, Richie JP, Zeckhauser RJ.
surveillance: results from The CaPSURE Predictors of patient preferences and
database. Cancer of the Prostate Strategic treatment choices for localized prostate
Urological Research Endeavor. J Urol cancer. Cancer 2008;113:2058-2067.
2000;164:81-88.
179. Meng MV, Elkin EP, Latini DM, et al.
169. Moses KA, Paciorek AT, Penson DF, et al. Treatment of patients with high risk
Impact of ethnicity on primary treatment localized prostate cancer: results from
choice and mortality in men with prostate cancer of the prostate strategic urological
cancer: data from CaPSURE. J Clin Oncol research endeavor (CaPSURE). Journal of
2010;28:1069-1074. Urology 2005;173:1557-1561.
170. Latini DM, Elkin EP, Cooperberg MR, et al. 180. Roberts CB, Albertsen PC, Shao YH, et al.
Differences in clinical characteristics and Patterns and correlates of prostate cancer
disease-free survival for Latino, African treatment in older men. Am J Med
American, and non-Latino white men with 2011;124:235-243.
localized prostate cancer: data from 181. van den Bergh RC, Essink-Bot ML, Roobol
CaPSURE. Cancer. 2006;106:789-795.
MJ et al. Anxiety and distress during active
171. Wolters T, Roobol MJ, Steyerberg EW, et surveillance for early prostate cancer.
al. The effect of study arm on prostate Cancer 2009;115:3868-3878.
cancer treatment in the large screening trial 182. Ramsey SD, Zeliadt SB, Fedorenko CR, et
ERSPC. Int J Cancer 2010;126:2387-2393.
al. Patient preferences and urologist
172. van As NJ, Norman AR, Thomas K, et al. recommendations among local-stage
Predicting the probability of deferred radical prostate cancer patients who present for
treatment for localised prostate cancer initial consultation and second opinions.
managed by active surveillance. Eur Urol World J Urol 2011;29:3-9.
2008;54:1297-1305.
183. Davison BJ, Oliffe JL, Pickles T, et al.
173. Mills N, Metcalfe C, Ronsmans C, et al. A Factors influencing men undertaking active
comparison of socio-demographic and surveillance for the management of low-risk
psychological factors between patients prostate cancer. Oncol Nurs Forum
consenting to randomisation and those 2009;36:89-96.
selecting treatment (the ProtecT study).
Contemp Clin Trials 2006;27:413-419. 184. Durham J, Low M, McLeod D. Screening
for prostate cancer: a survey of New
174. el-Geneidy M, Garzotto M, Panagiotou I, et Zealand general practitioners. N Z Med J
al. Delayed therapy with curative intent in a 2003;116:U476.
contemporary prostate cancer watchful-
waiting cohort. BJU Int 2004;93:510-515.
101
